AU2012292116A1 - Use of the antibody I-3859 for the detection and diagnosis of cancer - Google Patents

Use of the antibody I-3859 for the detection and diagnosis of cancer Download PDF

Info

Publication number
AU2012292116A1
AU2012292116A1 AU2012292116A AU2012292116A AU2012292116A1 AU 2012292116 A1 AU2012292116 A1 AU 2012292116A1 AU 2012292116 A AU2012292116 A AU 2012292116A AU 2012292116 A AU2012292116 A AU 2012292116A AU 2012292116 A1 AU2012292116 A1 AU 2012292116A1
Authority
AU
Australia
Prior art keywords
cxcr4
sequence seq
cdr
antibody
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012292116A
Other languages
English (en)
Inventor
Alexandra Jouhanneaud
Christine Klinguer-Hamour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2012292116A1 publication Critical patent/AU2012292116A1/en
Priority to AU2017204043A priority Critical patent/AU2017204043A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2012292116A 2011-07-29 2012-07-30 Use of the antibody I-3859 for the detection and diagnosis of cancer Abandoned AU2012292116A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204043A AU2017204043A1 (en) 2011-07-29 2017-06-15 Use of the antibody I-3859 for the detection and diagnosis of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
US61/513,345 2011-07-29
EP11306000.8 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204043A Division AU2017204043A1 (en) 2011-07-29 2017-06-15 Use of the antibody I-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
AU2012292116A1 true AU2012292116A1 (en) 2014-02-06

Family

ID=47628653

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012292116A Abandoned AU2012292116A1 (en) 2011-07-29 2012-07-30 Use of the antibody I-3859 for the detection and diagnosis of cancer
AU2017204043A Abandoned AU2017204043A1 (en) 2011-07-29 2017-06-15 Use of the antibody I-3859 for the detection and diagnosis of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204043A Abandoned AU2017204043A1 (en) 2011-07-29 2017-06-15 Use of the antibody I-3859 for the detection and diagnosis of cancer

Country Status (14)

Country Link
US (1) US20140170677A1 (enExample)
EP (1) EP2736926A1 (enExample)
JP (1) JP6138780B2 (enExample)
KR (1) KR20140047127A (enExample)
CN (1) CN103717620A (enExample)
AR (1) AR087363A1 (enExample)
AU (2) AU2012292116A1 (enExample)
BR (1) BR112014001979A2 (enExample)
CA (1) CA2842552A1 (enExample)
IL (1) IL230693A0 (enExample)
MX (1) MX2014001160A (enExample)
RU (1) RU2636032C2 (enExample)
WO (1) WO2013017562A1 (enExample)
ZA (1) ZA201400500B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
JP6780910B2 (ja) * 2015-10-23 2020-11-04 ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ 細胞間空間的近接を導き出すためのコンピュータ方法及びシステム
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
JP6332780B2 (ja) 2016-03-29 2018-05-30 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JP2021502071A (ja) * 2017-11-07 2021-01-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんバイオマーカーおよびその使用方法
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308996A1 (en) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP2324839B1 (en) 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
JP6138780B2 (ja) 2017-05-31
WO2013017562A1 (en) 2013-02-07
MX2014001160A (es) 2014-07-14
ZA201400500B (en) 2014-11-26
KR20140047127A (ko) 2014-04-21
BR112014001979A2 (pt) 2017-02-21
EP2736926A1 (en) 2014-06-04
RU2636032C2 (ru) 2017-11-17
IL230693A0 (en) 2014-03-31
US20140170677A1 (en) 2014-06-19
CA2842552A1 (en) 2013-02-07
RU2014103054A (ru) 2015-09-10
JP2014523920A (ja) 2014-09-18
CN103717620A (zh) 2014-04-09
AR087363A1 (es) 2014-03-19
AU2017204043A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US9518120B2 (en) Anti-CXCR4 antibody and its use for the detection and diagnosis of cancer
JP6138780B2 (ja) 癌の検出および診断のための抗体ｉ−３８５９の使用
US20210018508A1 (en) Igf-1r antibody and its use for the diagnosis of cancer
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
TW201311726A (zh) 抗體ｉ－３８５９用於癌症偵測及診斷之用途
CA3009768C (en) Compositions and methods for assessing the risk of cancer occurrence
OA18453A (en) IGF-1R antibody and its use for the diagnosis of cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted